Skip to main content
. 2014 Mar 6;2014(3):CD005467. doi: 10.1002/14651858.CD005467.pub2

Li ZY 2006.

Methods Country: China
Setting: hospital based
Aim: to study the effects of Xianling Gusong capsules in the treatment of postmenopausal osteoporosis
Study design: randomised controlled trial
Analysis: T‐test, Chi2 test, Ridit test
Loss to follow‐up: not reported
Participants Ethnicity: Chinese
43 postmenopausal osteoporosis patients enrolled: 21 in trial group, 22 in control group
Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA
Exclusion criteria: secondary osteoporosis, liver or kidney disease
Interventions Experimental: Xianling Gusong capsules (4 capsules, 3 times a day), for 6 months
Control: Caltrate (1 pill, twice a day), for 6 months
Outcomes BMD
Notes No funding sources or declarations of interest for the primary researchers reported
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence generation Unclear risk No information provided
Allocation concealment Unclear risk No information provided
Blinding 
 All outcomes Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed 
 All outcomes Low risk No missing outcome data
Free of selective reporting Unclear risk Not all the outcomes that were of interest in this review were reported
Free of other bias Low risk The study appears to be free of other sources of bias